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CLINICAL UPDATE
Occam’s razor: Intervene early to prevent
more strokes!
A. Ross Naylor, MD, FRCS, Leicester, United Kingdom
The early risk of stroke after a patient suffers a transient ischemic attack (TIA)/minor stroke is significantly higher than
previously thought. In most health systems, this (unfortunately) means that many vulnerable patients will have suffered
their stroke before having had any chance of being considered for carotid endarterectomy (CEA) or carotid angioplasty
with stenting (CAS). The problem is then compounded by institutional delays in finally undertaking CEA/CAS, which
leads to even greater diminishing benefit to the patient. Notwithstanding the fact that the international trials used a
6-month threshold for inclusion, it remains an unpalatable fact that if CEA/CAS is delayed beyond 12 weeks in
symptomatic patients with North American Symptomatic Carotid Endarterectomy Trial (NASCET) 50% to 99%
stenoses, the patient is exposed to all of the risks of intervening, but gains little in the way of long-term stroke prevention.
The take-home message is, therefore, very simple; “intervene early to prevent more strokes”. Occam’s razor has never been
sharper! ( J Vasc Surg 2008;48:1053-9.)William of Occam (AD 1285-1349) is credited with
introducing the “Law of Parsimony”, which states that “the
simplest explanation is usually the best”, the word “razor”
symbolizing the elimination of unnecessary assumptions from
the debate. Notwithstanding its antiquity, the principle un-
derlying Occam’s razor is of particular relevance in the debate
about the optimal timing for intervention in patients suffering
a transient ischemic attack (TIA) or minor stroke.
Most guidelines recommend that carotid endarterec-
tomy (CEA) is undertaken “promptly” after onset of symp-
toms. However, there is evidence that this does not occur in
the majority of symptomatic patients.1 The reasons are
multifactorial and include: (1) a lower political priority for
treating patients with cerebrovascular disease compared
with cancer or heart disease; (2) a perception that once the
neurological deficit associated with a TIA/minor stroke has
resolved, the early risk of recurrent stroke is relatively low;2
(3) an inability/unwillingness for health systems to regard
TIA/minor strokes as being emergencies similar to unsta-
ble angina or myocardial infarction; (4) logistical problems
regarding access to duplex, magnetic resonance angiogra-
phy (MRA), or computed tomographic angiography (CTA)
within hours of TIA; (5) inadequate patient/physician
education about the symptoms of TIA/minor stroke; (6) a
reluctance to leave elective theatre lists “unfilled” so that
urgent procedures can be added nearer the time; (7) a ten-
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doi:10.1016/j.jvs.2008.06.044dency to believe that provided CEA is performed within 6
months (one is complying with the findings of the interna-
tional trials); (8) a tendency to allocate disproportionately
more effort towards treating asymptomatic individuals; (9) a
lack of awareness (or simply ignoring) published data docu-
menting the benefits of intervening early in symptomatic
patients; (10) a professional/financial reluctance to work up a
patient for CEA and then allocate him/her to a colleague who
can operate sooner; and (11) a perception that early interven-
tions are more likely to be associated with increased proce-
dural risks that could precipitate medico-legal or professional
censure. In short, it is easy to blame “inadequacies in the
system” for much of the failures to treat TIA patients more
quickly, but “factors 7 through 11” have also influenced
surgical practice more than many of us might wish to admit.
BACK TO BASICS?
So why is “intervening early” so beneficial and how can
the logistical/professional concerns of the provider and
surgeon be reconciled? More importantly, is it possible to
identify “high risk for stroke” subgroups in order to opti-
mize resource utilization and patient benefit? The data
presented in Table I (risk of stroke after a TIA) and Table II
(effect of delay to CEA on late stroke prevention) are
crucial to understanding why there is currently much
greater emphasis on treating TIA/minor stroke patients as
emergencies. Traditional teaching holds that the 7-day risk
of stroke after suffering a TIA is 1% to 2%, rising to 2% to 4%
at 30 days.3 At these low levels of risk, most surgeons and
providers saw little need to change practice. Accordingly, 6
months has remained the accepted threshold for treating
the “recently symptomatic” patient. However, these “nat-
ural history” data were intrinsically flawed because the
constituent studies recruited patients well after the index
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excluded, while significant bias was introduced by method-
ological issues (such as outpatient vs emergency room vs
population based recruitment, follow-up method).4
Two recent meta-analyses4,5 reviewed the early risk of
stroke after TIA (Table I). Overall, the 2-day risk of stroke
was 3.1% increasing to 5.2% at 7 days and 8.0% at 30 days.
While this represents a doubling of risk (compared with
“traditional” teaching), they are still misleading and subject
to bias because of the different ways in which patients were
recruited and followed up. For example, Table I details the
early risk of stroke after TIA in studies where “passive”
follow-up was employed (ie, computerized hospital data-
bases were interrogated to identify patients suffering a
stroke rather than speaking to the patient).5 In this type of
study, patients who suffered a stroke and who were not
hospitalized, or who attended an alternative hospital, or
who suffered their stroke on the day of the TIA would not
be identified.4 Not surprisingly, the observed 30-day risk in
this type of study (6.4%) was less than that observed in the
meta-analysis overall (8.0%). Accordingly, reliance on type of
study would underestimate the true risk of stroke after a TIA.
By contrast, TIA patients recruited into population based
studies with “face to face” follow-up (and no urgent interven-
tions) had the worst prognosis (Table I) with a 2-day stroke
risk of 6.7%, increasing to 10.4% at 7 days, and 13% at 30 days.
In effect, this 30-day risk is four to six times greater than is
traditionally taught, with the highest risk period being the first
7 days. This finding was corroborated in a pooled cohort of
549 patients whose stroke was preceded by a TIA; 43% of
index TIAs occurred within 7 days of the stroke, while 17%
actually happened on the same day as the stroke.6
DELAY TO SURGERY FURTHER COMPOUNDS
THE PROBLEM
Having established that the early prognosis after suffer-
ing a TIA had been underestimated, a second challenge to
practice arose following a reanalysis of data from the inter-
national randomized trials. The European Carotid Surgery
Trial (ECST) and the North American Symptomatic Ca-
rotid Endarterectomy Trial (NASCET) published in
19917,8 and for the next 15 years, a 6-month threshold for
intervention assumed a “one size fits all” role. In reality,
this assumption meant that intervening on a patient with an
80% stenosis 5 months and 29 days after suffering their TIA
conferred exactly the same benefit (regarding late stroke
Table I. The early risk of stroke after TIA is much
greater than was originally thought
2 Days 7 Days 30 Days
“Traditional” teaching — 1%-2% 2%-4%
Meta-analyses (overall) 3.1%4 5.2%4 8.0%5
“Passive” ascertainment 3.1%5 — 6.4%5
“Face to face” follow-up 6.7%4 10.4%4 13.4%5
TIA, Transient ischemic attack.prevention) as if it were undertaken within 3 days of symp-tom onset. More importantly, many surgeons viewed a
little delay within the system (provided it was within the
6-month threshold) as being potentially beneficial, because
it was generally believed that urgent CEA was associated
with increased procedural risks (see later).
The Carotid Endarterectomy Trialists Collaboration
(CETC) combined data from 6000 patients recruited
into the ECST, NASCET, and VA trials, having remea-
sured prerandomization angiograms using the NASCET
method.9-11 These data have provided vital information
regarding the effect of delay upon outcome and patient
benefit. Table II details the absolute risk reduction (ARR)
conferred by CEA, the number needed to treat to prevent
one stroke at 5 years (NNT), and the number of ipsilateral
strokes prevented at 5 years per 1000 CEAs, stratified for
degree of stenosis (50%-69%, 70%-99%) and gender. The
term “delay” means time from symptom onset to random-
ization. In ECST and NASCET, the mean delay from
randomization to surgery was 7 days (PM Rothwell, per-
sonal communication). Table II clearly shows that the
magnitude of benefit conferred by CEA was highest in
patients with 70% to 99% (vs 50% to 69%) and in patients in
whom delays were least. The reduction in benefit as delays
increased was most apparent in patients with 50% to 69%
stenoses and after 12 weeks, CEA appeared to confer no
benefit at all. Patients with 70% to 99% stenoses gained
consistently greater benefit from CEA, but the magnitude
of stroke prevention still fell by 66% in patients in whom
12 weeks had elapsed.
More disturbing, however, were the data that emerged
when the CETC stratified for gender.11 Symptomatic
males with 50% to 69% stenoses gained diminishing benefit
with time, while the benefit conferred in male patients with
70% to 99% stenoses was largely preserved (Table II). In the
latter patients, approximately 200 ipsilateral strokes were
prevented at 5 years by performing 1000 CEAs irrespective
of whether delays were2 weeks or12 weeks. However,
the findings were totally different in women and really do
question whether existing practices actually confer any real
benefit at all (Table II). Symptomatic females with moder-
ate (50%-69%) stenoses only gained benefit from CEA if the
delay was 2 weeks. Thereafter, CEA may have been
associated with harm. A similar trend was evident in symptom-
atic female patients with 70% to 99% stenoses. Here, consid-
erable benefit was apparent provided the delay from onset of
symptoms to randomization was4 weeks. Thereafter, CEA
did not appear to confer any significant benefit at all.
How should these data be interpreted? Unfortunately,
the trials did not document the time from onset of symp-
toms to CEA. Accordingly, 7 days should be added to each
“delay grouping” in Table II to correct for this. This
limitation should not, however, detract from the funda-
mental message. If nothing else, these data have shown that
future guidelines cannot uncritically support perpetuation
of a practice that does not recognize that delays to inter-
vention (CEA or CAS) means rapidly diminishing benefit
to the patient, especially females. For example, it has be-
come conventional (especially in North America and main-
measu
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patients with NASCET 50% to 99% stenoses. The CETC
data suggest that if CEA is performed within 2 weeks, 185
ipsilateral strokes will be prevented at 5 years per 1000
CEAs (ie, highly effective). If, however, CEA is delayed by
12 weeks, the number of strokes prevented falls to eight
(ie, 992 unnecessary interventions.1) Many readers will
claim that this type of delay is not representative of their
practice, but the published evidence suggests this not to be
the case.1
SO WHERE NEXT?
Faced with compelling evidence that the natural
history risk of stroke after TIA had been grossly under-
estimated and that delays to surgery diminished the
overall benefit conferred to the patient even further, the
UK Government recently published a National Stroke
Strategy. The aim was to raise public/professional
awareness of TIA/stroke, as well as making radical
changes to existing practices for investigating and treat-
ing patients.12 This strategy has been well received, but it
does have major implications for service provision and
clinical practice. It has also highlighted several important
issues affecting providers and surgeons. The first relates
to the logistics of how to provide such a service (is it
possible to identify “high risk” subgroups within cohorts
of patients presenting with a TIA?). The second relates to
concerns by surgeons that expedited surgery will inevi-
tably lead to increased procedural risks that could either
negate any long-term benefit to the patient or render the
surgeon liable to medico-legal and/or professional cen-
sure. There is also the important issue of whether such a
Table II. Absolute risk reduction conferred by CEA in th
(including the perioperative risk) in patients with a NASCE
from index event to randomization and gendera
50%-69% Stenosis
ARR NNT C
(1) All patients
2 weeks 14.8% 7
2-4 weeks 3.3% 30
4-12 weeks 4.0% 25
12 weeks 2.9% nb
(2) Males
2 weeks 15.2% 7
2-4 weeks 6.8% 15
4-12 weeks 5.0% 20
12 weeks 6.3% 16
(3) Females
2 weeks 13.8% 7
2-4 weeks 5.7% nb
4-12 weeks 2.2% nb
12 weeks 21.7% nb
ARR, Absolute risk reduction (%) conferred by surgery over best medica
number of CEAs needed to be performed to prevent one stroke at 5 years;
1000 CEAs; nb, no benefit conferred by CEA.
aData derived from the CETC9-11 with all prerandomization angiograms restrategy will apply to practitioners of carotid angioplastywith stenting (CAS). None of the randomized trials
comparing CEA with CAS in symptomatic patients have
stratified their outcomes to correct for delay from onset
of symptoms to intervention.
IDENTIFYING THE “HIGH RISK FOR
STROKE” PATIENT
There have been a number of attempts to develop
clinically useful scoring systems for identifying high risk
patients in the first 7 days after TIA onset. The ABCD and
Californian Scoring systems have been extensively evalu-
ear risk of ipsilateral carotid territory ischemic stroke
0% to 69% and 70% to 99% stenosis, stratified for delay
70%-99% Stenosis
1000 ARR NNT CVA/1000
8 23.0% 4 230
3 15.9% 6 159
0 7.9% 13 79
7.4% 14 74
2 23.3% 4 233
8 23.8% 4 238
0 18.3% 5 183
3 20.4% 5 204
8 41.7% 2 417
6.6% 15 66
2.2% nb nb
2.4% nb nb
py; CEA, carotid endarterectomy; CVA, cardiovascular accident; NNT,
/1000, number of ipsilateral strokes prevented at five years by performing
red using NASCET method.
Table III. Prediction of early stroke risk after suffering a
TIA: the ABCD2 scoring systema
Score
A Age 60 1
B Blood pressure Systolic 140 mm Hg or 1
Diastolic 90 mm Hg
C Clinical features Unilateral weakness 2
Speech impairment (no weakness) 1
D Duration of TIA 60 min 2
10-59 min 1
D Diabetes Diabetes 1
Max score 7
ABCD2 Risk of stroke
Score n  2-Day 7-Day 90-Day
0-3 1628 1.0% 1.2% 3.1%
4-5 2169 4.1% 5.9% 9.8%
6-7 1012 8.1% 11.7% 17.8%
aData derived from Johnston.13e 5-y
T 5
VA/
14
3
4
nb
15
6
5
6
13
nb
nb
nb
l thera
CVAated and combined within two derivation and four valida-
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the ABCD2 score.13 Table III summarizes the criteria as
well as the 2-, 7-, and 90-day risk of stroke stratified for the
ABCD2 score. Note that patients with a score 3 have a
very low stroke risk (1% at 2 days, 1.2% at 7 days, and 3.1%
at 90 days). Early stroke risk increased in patients scoring
4, with the greatest risk being seen in patients scoring 6-7
(2-day risk of stroke 8.1%, 7-day risk of stroke 11.7%).
The UK National Stroke Strategy recommends that any
patient with an ABCD2 score of 3 should be assessed
within 7 days of onset of symptoms (ie, not as an acute
emergency). However, those scoring 4 need to be as-
sessed and investigated (MR, CT, duplex) by a stroke
specialist24 hours of onset of symptoms. Patients with an
ABCD2 score of 4 and a 50% to 99% ipsilateral carotid
stenosis should be admitted to hospital and CEA per-
formed within 48 hours unless contra-indicated. The obvi-
ous caveat is the patient who presents some time after the
index event. They would qualify for being seen within the
7-day (nonurgent) threshold. This strategy will clearly re-
quire a major reorganization of the way vascular technolo-
gists, surgeons, and hospital services work and will, of
course, have to include access to cerebral vascular clinics on
a daily basis (including weekends).
SMOKE AND MIRRORS!
In the current era of league tables, increasing account-
ability and litigation, any recommendation to undertake
the majority of CEAs within 1 to 2 weeks of a TIA/minor
stroke is going to arouse concerns. First, is whether the
prognosis in patients presenting with a minor stroke is
similar to that cited for TIA patients? If the answer is yes,
the second issue is how can the advice to intervene early be
reconciled with traditional teaching that recommends de-
ferring surgery for 6 to 8 weeks in patients who have
suffered a stroke? Third, most surgeons will intuitively
believe that expedited/urgent surgery is associated with
increased procedural risks. If that is the case, won’t these
increased risks negate any long-term benefit? Moreover,
how can the surgeon be reassured that an increase in
procedural risk will not make him/her liable to uncritical
professional censure?
The first question is surprisingly difficult to answer,
especially using population based data. Although there
have been a number of conflicting studies, Coull14 showed
that (if anything) patients presenting with a minor stroke
faced an equivalent or slightly worse early prognosis than
their TIA counterparts (11.5% stroke risk at 7 days, 15% at
30 days). Accordingly, if surgeons continue to defer sur-
gery for up to 6 weeks, the majority of vulnerable patients
will have suffered their stroke before having any chance of
undergoing CEA or CAS. There is also evidence that
patients who recover neurological function early after a
minor stroke may be at increased risk of suffering early
secondary neurological deterioration.15 For these reasons,
the UK National Stroke Strategy recommendations for
treating TIA and minor stroke patients expeditiously are
the same.12This recommendation is, however, at odds with “tradi-
tional” teaching which states that CEA should be deferred
for 6 weeks in stroke patients. This recommendation fol-
lowed poor outcomes in the 1960s (especially hemorrhagic
transformation of an ischemic infarct) when patients suffer-
ing an acute thrombotic stroke were subjected to emer-
gency surgery. Many of these patients, however, presented
with acute carotid thromboses, had dense neurological
deficits or were neurologically obtunded. Since then, most
surgeons would never consider this genre of patient as
being appropriate for emergency intervention and over the
last 40 years, the quality of anesthesia, blood pressure
control, and intensive care therapy has improved dramati-
cally. Despite this, however, the “6-week rule” has en-
dured, even in patients who make a rapid neurological
recovery.
In a subgroup analysis, NASCET were one of the first
to challenge this doctrine having shown that although
patients presenting with a minor stroke in whom CEA was
deferred for30 days were more likely to have an abnormal
CT, there was no difference in the perioperative risk (CEA
30 days [4.8%],30 days [5.2%]). Nor was the operative
risk increased in patients with an infarct on CT scan (30
days [0.0%],30 days [5.4%]).16 A number of studies have
reported similar findings and a meta-analysis has shown no
evidence of a significant increase in risk if CEA is performed
early.17 Unfortunately, NASCET used 4 weeks for the
definition of early vs late, while the meta-analysis used up to
6 weeks. Table IV summarizes those few published series
where CEA was performed within 14 days. As can be seen,
most patients presented with a stroke.18 Huber’s series was
unique in that they included patients with completed
strokes, crescendo TIAs, severe (Rankin 3-5) neurological
deficits and some with acute carotid occlusion.26 Not sur-
prisingly, the procedural risk (16.4%) was much higher than
the others. Accordingly, the concept of “picking winners”
will remain crucial. The type of minor stroke patient liable
to be selected for urgent CEA will have made a relatively
rapid recovery from their deficit or will have a neurological
plateau. They will not have carotid occlusion, they will be
Rankin 0-2 in terms of disability, the area of infarction
should not exceed one third of the middle cerebral artery
territory, there should be no intracranial hemorrhage, and
patients should be lucid and able to give informed con-
sent.18 All other patients (ie, those with more severe defi-
cits) should have CEA deferred on the grounds that the
benefits of early intervention are still outweighed by the
risks.
Given these caveats, Rantner’s series of 226 patients is
probably the most relevant study as this was much larger
than the others and was derived from a collaboration of
three prospective databases. Two-thirds of patients pre-
sented with a minor stroke. Overall, 226 patients under-
went CEA within a median of 48 hours after onset of
symptoms incurring a 30-day death/stroke rate of 8.4%.25
Some might view this risk as being excessive (and further
evidence that CEA should have been deferred) but (hope-
fully) the next section will suggest this not to be the case.
l risk b
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(should urgent CEA/CAS become standard practice) is
whether this will be associated with increased procedural
risks. One of the catalysts for this debate was publication of
outcomes following1000 CEAs in symptomatic patients
which included stratification for delay from presentation to
surgery.27 Patients undergoing CEA4 weeks of symptom
onset faced a threefold increase in the procedural risk
compared with patients in whom surgery was deferred for
4 weeks (5.1% vs 1.6%). The author’s clear message was
that patients would benefit from deferred surgery in order
to minimize the procedural risk.
Bazan reviewed outcomes following 764 CEAs per-
formed for “urgent” indications in all acute, nonfederal
Connecticut hospitals between 1992 and 2002.28 They did
not state the delay to surgery (although by implication,
CEA must have been performed soon after admission) and
outcomes were stratified according to the All Patient Re-
fined Diagnosis Related Groups (APR-DRG) risk mortality
variable (3M Health Information Systems, St Paul, Minn).
Patients were classed as low comorbidity if they were grade
1 (minor) or 2 (moderate) and high comorbidity if they
were grade 3 (major) or 4 (extreme severity). Overall,
patients undergoing “urgent” CEA with a low comorbidity
score had similar 30-day risks to patients undergoing elec-
tive CEA during the same time period. By contrast, “ur-
gent” CEA patients with high comorbidity suffered signif-
icantly higher mortality rates than their “urgent” but low
comorbidity counterparts (7.8% vs 0.4%). Perioperative
stroke was also significantly higher (10.9% vs 0.8%). How-
ever, if one excluded the grade 4 (extremely severe) patients
and only included grade 3 within the category of “high
comorbidity”, mortality fell to 5.8% and stroke to 3.9%.28
Table IV. Thirty-day death/stroke rates following CEA w
symptoms
Reference Year n  Symptom
Median
even
Ricco19 2000 72 CVA 5.5 (ra
Paty20 2004 72 CVA
Paty20 2004 131 CVA 
Dorigo21 2007 70 CVA/TIA
Aleksic22 2006 50 CVA/TIA 4.5 (ra
Karkos23 2007 42 TIAb 3.0 (ra
Sbarigia24 2006 96 CVA 1.5 (ra
Rantner25 2006 226 CVA 12 (IQ
Huber26 2003 67 CVA/TIAc 2.0 (ra
CEA, Carotid endarterectomy; TIA, transient ischemic attack; CVA, cardio
aPrevalence of intracranial hemorrhage.
bCohort had suffered 3 TIAs in preceding 7 days.
cMixed cohort including completed strokes, crescendo TIAs and patients
Neurological Event Severity Score.
eNIHSS, National Institute of Health Stroke Scale.
fIndependent neurological verification of outcomes.
gPostop CT scans only done in patients with worsening/new neurological
hNew hemorrhage present on CT scan, but not associated with symptoms.
Reproduced with permission from Naylor AR. Delay may reduce proceduraOnce again, the message is to pick winners.Interestingly, a similar debate is emerging in the CAS
literature. The CAPTURE Registry observed that patients
presenting with a TIA/minor stroke who underwent pro-
tected CAS within 14 days of symptom onset had a signif-
icantly higher risk of suffering a procedural stroke (odds
ratio 2.52 [95% confidence interval 1.33-4.78].29 After 14
days had elapsed, this excess risk disappeared. Two other
CAS studies are worthy of note. In a relatively small series
(n  77), Topakian30 noted that patients presenting with
TIA/stroke who underwent protected CAS within 14 days
of symptom onset suffered a significantly higher 30-day
death/stroke rate than patients undergoing deferred CAS
(26.1% vs 1.9%). In response to this, Groschel31 reviewed
their own experience (n 320) and noted no difference in
30-day death/stroke relative to whether CAS was per-
formed14 days (7.0%) or14 days (9.6%). This is clearly
a very important issue and may be one of the reasons why
the EVA-3S study encountered a 9.6% 30-day death-stroke
rate in its CAS patients. Ignored by many of the critics of
EVA-3S was data showing that 20% of patients underwent
CAS within 14 days of onset of symptoms, while another
25% underwent CAS between 14 to 28 days after symptom
onset. Overall, 45% of CAS patients underwent interven-
tion within 28 days of presentation.32 Hopefully, the prin-
ciple randomized trials comparing CEA with CAS will
combine their data and specifically look at the effect of delay
to intervention on procedural risk.
On balance, the available evidence does suggest that
the 30-day risk does increase if CEA or CAS is undertaken
within 14 days of onset of symptoms. The final question,
therefore, is whether this is a reason for recommending
deferring any intervention so that risks become lower. The
CETC have provided useful information for this particular
performed within a median of 14 days since onset of
s from
EA Stroke score
30-day
death/stroke ICHa
-15) NESS  3d 2.8% 0.0%g
“nondisabling” 2.8% not stated
“nondisabling” 3.1% not stated
“nondisabling” 5.4%f not stated
-21) Rankin 4 6.0% 4.0%h
-7) Rankin 4 7.0% 0.0%g
-11) NIHSS 22e 7.3%f 0.0%g
-19) 66% Rankin 2 8.4%f 0.4%g
-18) 48% Rankin 3-5 16.4%f 1.5%g
lar accident.
carotid occlusion and severe (Rankin 3-5) neurological deficits, dNESS,
. None of these had CT evidence of new hemorrhage.
ut at what price to the patient? Eur J Vasc Endovasc Surg 2008;35:383-91.hen
day
t to C
nge 2
7
14
2.0
nge 1
nge 1
nge 1
R 8
nge 0
vascu
with
deficitdebate. The Fig presents a reanalysis of the CETC database
JOURNAL OF VASCULAR SURGERY
October 20081058 Naylorfor patients presenting with a 50% to 99% stenosis, stratified
for timing from event to randomization and the 30-day
death/stroke after CEA.1 Note that performing CEA (or
CAS) with a 10% risk within 14 days will prevent approxi-
mately 150 strokes at 5 years per 1000 CEAs. By contrast,
if one were to defer CEA/CAS until4 weeks had elapsed
and then undertake that intervention with a 3% risk, only
100 strokes would be prevented.1,18 The key message is
that while the procedural risk may indeed be higher by
intervening very early, you will actually be preventing many
more strokes than by delaying the intervention. This is a
very important concept for guideline makers to incorporate
in future recommendations. Otherwise, surgeons and in-
terventionists will be reluctant to treat patients expedi-
tiously if it then meant that they were liable to being labeled
as “poor performers” when compared in a league table with
colleagues who simply deferred their interventions so as to
achieve the lowest possible procedural risks.
In conclusion, the early risk of stroke after a patient
suffers a TIA/minor stroke is significantly higher than was
previously thought. In most health systems, this (unfortu-
nately) means that many vulnerable patients will have suf-
fered a stroke before having had any chance of being
considered for either CEA or CAS. The problem is then
compounded by institutional delays in undertaking CEA/
CAS, which leads to even further diminishing benefit to the
patient. Notwithstanding the fact that the international
trials used a 6-month threshold for inclusion, it remains an
unpalatable fact that if CEA/CAS is delayed beyond 12
weeks in symptomatic patients with NASCET 50% to 99%
stenoses, the patient is exposed to all of the risks of inter-
vening, but gains little in the way of long-term stroke
prevention. The take-home message is, therefore, very sim-
ple; “intervene early to prevent more strokes”. Occam’s
razor has never been sharper!
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